Please use this identifier to cite or link to this item:
|Title:||Prevalence and natural history of ALK positive non-small-cell lung cancer and the clinical impact of targeted therapy with ALK inhibitors.|
|Authors:||Chia, Puey Ling;Mitchell, Paul L R;Dobrovic, Alexander;John, Thomas|
|Affiliation:||Department of Medical Oncology, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia.|
Ludwig Institute for Cancer Research, Austin Health, Victoria, Australia ; Department of Pathology, University of Melbourne, Victoria, Australia ; School of Cancer Medicine, La Trobe University, Victoria, Australia.
Department of Medical Oncology, Olivia-Newton John Cancer and Wellness Centre, Victoria, Australia ; Ludwig Institute for Cancer Research, Austin Health, Victoria, Australia ; School of Cancer Medicine, La Trobe University, Victoria, Australia.
|Citation:||Clinical Epidemiology 2014; 6(): 423-32|
|Abstract:||Improved understanding of molecular drivers of carcinogenesis has led to significant progress in the management of lung cancer. Patients with non-small-cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) gene rearrangements constitute about 4%-5% of all NSCLC patients. ALK+ NSCLC cells respond well to small molecule ALK inhibitors such as crizotinib; however, resistance invariably develops after several months of treatment. There are now several newer ALK inhibitors, with the next generation of agents targeting resistance mutations. In this review, we will discuss the prevalence and clinical characteristics of ALK+ lung cancer, current treatment options, and future directions in the management of this subset of NSCLC patients.|
|Internal ID Number:||25429239|
|Subjects:||anaplastic lymphoma kinase (ALK)|
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.